8-K: Aimei Health Extends Business Combination Deadline

Aimei Health Technology Co., Ltd. secured a one-month extension for its initial business combination deadline to January 6, 2026, funded by a $34,330.96 promissory note.

Summary

• Aimei Health Technology Co., Ltd. (the Company) extended its initial business combination deadline by one month, from December 6, 2025, to January 6, 2026.
• This is the thirteenth extension permitted under the Company's Amended and Restated Articles of Association.
• An Extension Payment of $34,330.96 was deposited into the trust account for public shareholders, representing the lesser of $80,000 for all outstanding public shares or $0.033 per outstanding public share.
• The Company issued an unsecured promissory note for $34,330.96 to Aimei Health Ltd (the Sponsor) and United Hydrogen Group Inc. (the Payees) to fund the Extension Payment.
• Each Payee contributed $17,165.48.
• The Promissory Note does not bear interest and is due upon the consummation of a business combination with United Hydrogen.
• The Payees have the option to convert the Promissory Note into private units of the Company at $10.00 per unit, each consisting of one ordinary share and one right to receive one-fifth of one ordinary share, prior to the business combination.

Sentiment

Score: 4

Explanation: The extension provides more time, which is positive, but it's the thirteenth extension, indicating significant ongoing challenges. The reduction in trust account funds for public shareholders and the unsecured nature of the promissory note add to the negative sentiment, reflecting continued uncertainty and dilution of shareholder value.

Positives

• The Company secured a one-month extension, providing additional time to consummate its initial business combination.
• The extension payment ensures the continuation of the SPAC's operations towards a potential merger.
• The Promissory Note is unsecured and does not bear interest, reducing immediate financial burden on the Company.
• The Payees (Sponsor and United Hydrogen Group Inc.) are committed to funding the extension, indicating continued support for the business combination.

Negatives

• The need for a thirteenth extension suggests ongoing challenges in completing the initial business combination.
• The Extension Payment of $34,330.96 reduces the funds available in the trust account for public shareholders, potentially impacting their per-share redemption value if no business combination occurs.
• The Promissory Note's principal is only due upon consummation of the business combination, creating uncertainty if the deal falls through.

Risks

• Failure to consummate the initial business combination with United Hydrogen Group Inc. by the new Termination Date of January 6, 2026.
• The Promissory Note is unsecured, meaning Payees would be general creditors if the Company faces financial distress.
• The value of the private units into which the Promissory Note can be converted is subject to market conditions post-business combination.
• Public shareholders' funds in the trust account are being reduced by extension payments, potentially diminishing their return if the SPAC liquidates.

Future Outlook

The Company intends to use the extended period until January 6, 2026, to consummate its initial business combination with United Hydrogen Group Inc. The Promissory Note is structured to be repaid or converted upon the successful completion of this combination.

Management Comments

• "Aimei Health Technology Co., Ltd. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized."
• Junheng Xie, Chief Executive Officer and Director, signed the report.

Industry Context

The need for multiple extensions is common among Special Purpose Acquisition Companies (SPACs) that face challenges in identifying and closing suitable business combinations within their initial timeframe. This reflects a broader trend in the SPAC market where many vehicles struggle to complete mergers, often leading to liquidations or further extensions funded by sponsors.

Comparison to Industry Standards

• The thirteenth extension is a significant number, indicating prolonged difficulty in closing a deal, which is higher than the average for successful SPACs that typically complete mergers within a few extensions or the initial period.
• The extension payment structure, where the sponsor funds the trust account, is a standard mechanism for SPACs seeking to extend their lifespan.
• The conversion option for the promissory note into private units at $10.00 per unit is a common incentive for sponsors providing extension capital, aligning their interests with the successful completion of the business combination.

Related Party Transactions

• The Company issued an unsecured promissory note to Aimei Health Ltd (the Sponsor) and United Hydrogen Group Inc. (the target for the business combination).
• The Sponsor and United Hydrogen Group Inc. each contributed $17,165.48 to fund the Extension Payment.

Stakeholder Impact

• Shareholders: Public shareholders' per-share redemption value from the trust account is reduced by the $34,330.96 extension payment. Their investment remains in limbo pending the business combination.
• Sponsor (Aimei Health Ltd): Provides additional capital to extend the SPAC's life, maintaining its investment and potential for future returns if the business combination closes. Has the option to convert the note into private units.
• Target Company (United Hydrogen Group Inc.): Receives continued commitment from the SPAC for the business combination, with its own contribution to the extension payment and the option to convert the note into private units.

Next Steps

• Consummate the initial business combination with United Hydrogen Group Inc. by January 6, 2026.
• If the business combination is successful, the Promissory Note will become due and payable or convertible into private units.

Key Dates

Recommendation

While the extension provides more time for the business combination, it's the thirteenth such extension, signaling persistent difficulties and increasing uncertainty. The reduction in trust account value due to extension payments is a negative for public shareholders. An investor would likely hold, awaiting clearer progress on the business combination or considering redemption if the deal fails, rather than buying into further uncertainty or selling at a potential loss.

Keywords

SPAC, Aimei Health Technology, United Hydrogen Group, business combination, extension, promissory note, trust account, merger, AFJK, AFJKR, AFJKU, Nasdaq